Merck climbs to the top of vaccine market


Photo: Brian Hoskins


The analysts expect it that the second position will ? surprisingly ? become assumed by Merck company, with the sales revenue of USD 7.5 billion to be generated from the sales of vaccines in 2022. The company will be directly followed by Pfizer (USD 7.13 billion) and Sanofi (USD 6.8 billion). GlaxoSmithKline (GSK) will still be considered the leader, with its revenue to reach the level of USD 8.65 billion. According to analysts, the change is brought about by a forecast pertaining to the growth in sales of such Merk-manufactured products as those bearing the names of Gardasil and Pneumovax, and so consequently by USD 215 million and USD 268 million.

Less considerable growth, as falling within the range of USD 80-122 million, is expected to concern other products by the company as well ? namely, RotaTeq, Varivas, Proquad and Vaxelis. Moreover, the company is carrying out its works on Ebola vaccine, which may further improve its market position.

Initially, the analysts  have underestimated the significance of the manufacture of vaccines by Merck due to the Zostavax product (against Herpes zoster) that had caused the lowering of expectations with regard to the company by USD 168 million. This is related to the competition from GSK company which is launching yet another similar vaccine ? named Shingrix ?  into the market, being to cause the intensified battle for customers there. Consecutively, Sanofi has declined in the ranking, and so due to the fact that it is still struggling with the poor sales of Dengvaxia, whose development has consumed USD 1.5 billion, as well as 20 years of research. The vaccine generated the revenue of EUR 55 million last year, as opposed to the EUR 200 million of expected one which means that it is still selling below any expectations.

The four major corporations, namely GSK, Merck, Pfizer and Sanofi, will have taken over 85% of vaccine market by year 2022. It is being estimated that the top ten of largest companies related to this sector will also include CSL, Emergent BioSolutions, Novavax, Mitsubishi Tanabe, Astellas and AstraZeneca. CSL may additionally step into the position of Sanofi, as this concern has recently created Seqirus vaccine against influenza and is heading for achieving the leadership position.


Feel free to contact us.


Phone: +48 71 725 34 10

Office address
ul. E. Kwiatkowskiego 4, 52-326 Wrocław, Poland

© 2020 - Grupa Kapitałowa Startit Fund | All rights reserved.

Made in:

Important: I hereby confirm that I have read the Privacy Policy and Cookies Policy of Startit Fund Sp. z o.o. [Ltd.] company
Join us!